391 related articles for article (PubMed ID: 17397531)
1. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
2. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
[TBL] [Abstract][Full Text] [Related]
3. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection.
Ansaldi F; Bruzzone B; Testino G; Bassetti M; Gasparini R; Crovari P; Icardi G
J Viral Hepat; 2006 Jan; 13(1):5-10. PubMed ID: 16364076
[TBL] [Abstract][Full Text] [Related]
4. Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.
Castelain S; Schnuriger A; François C; Nguyen-Khac E; Fournier C; Schmit JL; Capron D; Dubuisson J; Wychowski C; Thibault V; Duverlie G
J Infect Dis; 2008 Aug; 198(3):332-5. PubMed ID: 18558868
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a total hepatitis C virus (HCV) core antigen assay for the detection of antigenaemia in anti-HCV positive individuals.
Valcavi P; Medici MC; Casula F; Arcangeletti MC; De Conto F; Pinardi F; Calderaro A; Chezzi C; Dettori G
J Med Virol; 2004 Jul; 73(3):397-403. PubMed ID: 15170635
[TBL] [Abstract][Full Text] [Related]
6. Detection of antibodies to hepatitis C virus: false-negative results in an automated chemiluminescent microparticle immunoassay (ARCHITECT Anti-HCV) compared to a microparticle enzyme immunoassay (AxSYM HCV Version 3.0).
Myrmel H; Navaratnam V; Asjø B
J Clin Virol; 2005 Nov; 34(3):211-5; discussion 216-8. PubMed ID: 16112611
[TBL] [Abstract][Full Text] [Related]
7. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
[TBL] [Abstract][Full Text] [Related]
9. TaqMan amplification system with an internal positive control for HCV RNA quantitation.
Castelain S; Descamps V; Thibault V; François C; Bonte D; Morel V; Izopet J; Capron D; Zawadzki P; Duverlie G
J Clin Virol; 2004 Nov; 31(3):227-34. PubMed ID: 15465417
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the available anti-HCV antibody detection tests and RT-PCR assay in the diagnosis of hepatitis C virus infection.
Tashkandy MA; Khodari YA; Ibrahim AM; Dhafar KO; Gazzaz ZJ; Azab BA
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):523-31. PubMed ID: 17951937
[TBL] [Abstract][Full Text] [Related]
11. Antigenic relevance of F protein in chronic hepatitis C virus infection.
Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the patients with low levels of anti-HCV positivity].
Zer Y; Karaoğlan I; Ciçek H; Karağoz ID; Sağlam M
Mikrobiyol Bul; 2009 Jan; 43(1):133-9. PubMed ID: 19334390
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
[TBL] [Abstract][Full Text] [Related]
15. [Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals].
Schnuriger A; Dominguez S; Valantin MA; Tubiana R; Duvivier C; Ghosn J; Simon A; Katlama C; Thibault V
Pathol Biol (Paris); 2006 Dec; 54(10):578-86. PubMed ID: 17030457
[TBL] [Abstract][Full Text] [Related]
16. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).
Berger A; Giroglou T; Leutz A; Ogbomo H; Pfaff K; Teuber G; Cinatl J; van Laer D; Doerr HW
J Clin Virol; 2009 Sep; 46(1):55-60. PubMed ID: 19560398
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of two hepatitis C virus typing assays in a Tunisian population].
Ben Moussa M; Barguellil F; Bouziani A; Amor A
Ann Biol Clin (Paris); 2003; 61(2):234-8. PubMed ID: 12702482
[TBL] [Abstract][Full Text] [Related]
19. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans.
Muhamuda K; Madhusudana SN; Ravi V
Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
